Despite nationwide cohort studies revealing an increased risk of malignant melanoma (MM) in people with multiple sclerosis (PwMS), the connection between MS disease-modifying therapies (DMTs) and MM risk remains underexplored. We identified 1200 reports of MM associated with MS DMTs in the FDA Adverse Event Reporting System (FAERS), and a pooled analysis of all DMTs showed disproportionately high MM reporting compared to all other FAERS medications (reporting odds ratio, 2.30; 95% confidence interval, 2.16–2.45; χ2, 702.33). As MS DMTs may influence MM risk, clinicians should educate PwMS on the importance of regular skin self-examinations.
NørgaardMVeresKDiddenEM, et al. Multiple sclerosis and cancer incidence: A Danish nationwide cohort study. Mult Scler Relat Disord2019; 28: 81–85.
2.
KuiperJGOverbeekJAFochC, et al. Incidence of malignancies in patients with multiple sclerosis versus a healthy matched cohort: A population-based cohort study in the Netherlands using the PHARMO Database Network. J Clin Neurosci2022; 103: 49–55.
3.
KreherMAKondaSNolandMMB, et al. Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: Methotrexate, alkylating agents, biologics, and small molecule inhibitors. J Am Acad Dermatol2023; 88(3): 534–542.
4.
BöhmRvon HehnLHerdegenT, et al. OpenVigil FDA—Inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications. PLoS ONE2016; 11(6): e0157753.
5.
AlpingPAsklingJBurmanJ, et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Ann Neurol2020; 87(5): 688–699.
6.
Ruetsch-ChelliCOkudaDTRocherF, et al. Sphingosine-1 phosphate receptor modulators increase in vitro melanoma cell line proliferation at therapeutic doses used in patients with multiple sclerosis. Neurol Ther2023; 12(1): 289–302.
7.
StamatellosVPRigasAStamoulaE, et al. S1P receptor modulators in multiple sclerosis: Detecting a potential skin cancer safety signal. Mult Scler Relat Disord2022; 59: 103681.
8.
KelmRCHagstromELMathieuRJ, et al. Melanoma subsequent to natalizumab exposure: A report from the RADAR (Research on Adverse Drug events and Reports) program. J Am Acad Dermatol2019; 80(3): 820–821.
9.
CarboneMLLacalPMMessineseS, et al. Multiple sclerosis treatment and melanoma development. Int J Mol Sci2020; 21(8): 2950.
10.
YangKKaundinyaTKassamaliB, et al. Prevalence of self-skin exams and full body skin exams among patients with disabilities. Arch Dermatol Res2023; 315(8): 2419–2421.
